Oral fungal infection treatment shows promise in preclinical trials
A novel oral amphotericin B (MAT2203) developed by Matinas BioPharma for treatment of invasive mucormycosis (IM) and other deadly invasive fungal infections, has demonstrated encouraging results in a series of preclinical ...
Apr 30, 2024
0
0